<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161474">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01938495</url>
  </required_header>
  <id_info>
    <org_study_id>2013P001504</org_study_id>
    <nct_id>NCT01938495</nct_id>
  </id_info>
  <brief_title>Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>DPS in ALS</acronym>
  <official_title>Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Upstate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALS Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Muscular Dystrophy Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Synapse Biomedical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York - Upstate Medical University</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to determine if DPS treatment for people with ALS and
      hypoventilation is associated with improved survival or diaphragm function.

      The primary objective of the study is to conduct a multi-center, randomized controlled
      clinical trial comparing standard of care (control) to diaphragm stimulator treatment with
      the NeuRx® Diaphragm Pacing System™ (DPS) with respect to survival.

      The secondary objective of the study is to conduct a multi-center, randomized controlled
      clinical trial to compare standard of care treatment (control) to DPS in ALS subjects with
      hypoventilation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized controlled study to compare standard of care (control) to DPS
      (diaphragm stimulator named The NeuRx® Diaphragm Pacing System™). Although it remains
      uncertain if DPS is efficacious for the ALS subject, given the preliminary studies performed
      by the device manufacturer, it has received FDA humanitarian device exemption (HDE) approval
      as a humanitarian use device (HUD).  This study will utilize a 2:1 randomization schedule
      such that eligible ALS subjects will have a 2/3 chance of receiving DPS and 1/3 chance of
      standard of care (control) treatment.

      The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous
      diaphragm muscle stimulation system. Under general anesthesia, the intramuscular electrodes
      are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are
      tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an
      external stimulator.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Subjects will be assessed on a monthly basis for an 18 month period.</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>Subjects will be assessed on a monthly basis for an 18 month period.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>NeuRx® Diaphragm Pacing System™ (DPS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the experimental arm will receive The NeuRx® Diaphragm Pacing System™ (DPS) device. Under general anesthesia, the intramuscular electrodes are surgically implanted in the diaphragm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients randomized to the standard of care arm will not have the Diaphragm Pacing System surgically implanted but will receive standard medical care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuRx® Diaphragm Pacing System™ (DPS)</intervention_name>
    <description>The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.</description>
    <arm_group_label>NeuRx® Diaphragm Pacing System™ (DPS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 21 years or older.

          2. Sporadic or familial ALS diagnosed as definite, probable or possible ALS as defined
             by revised El Escorial criteria.

          3. Evidence of hypoventilation at Screening with at least one of the following:

               1. Maximal static inspiratory pressure (MIP) &lt;60 cm H20.

               2. Upright or supine forced vital capacity (FVC) &lt;50% predicted for gender, age,
                  and height.

          4. Both hemi-diaphragms must be able to be stimulated with a recordable compound muscle
             action potential (CMAP ≥ 0.1milivolts amplitude and distal latency ≤ 11 milliseconds)
             with standard phrenic nerve conduction studies.

          5. Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of
             riluzole for at least 30 days, prior to randomization (riluzole-naïve subjects are
             permitted in the study).

          6. Capable of providing informed consent and following trial procedures.

          7. Geographically accessible to the site.

          8. Negative urine pregnancy test at Screening in women of child bearing potential
             (WOCBP). (Women who are post-menopausal or who have had a hysterectomy are deemed not
             of child bearing potential).

          9. Women of child bearing potential must use an adequate form of contraception:
             abstinence, hormonal contraception (oral contraception, implanted contraception,
             injected contraception or other hormonal (patch or contraceptive ring, for example)
             contraception), intrauterine device (IUD) in place for ≥ 3 months, barrier method in
             conjunction with spermicide, or another adequate method.

        Exclusion Criteria:

          1. Upright forced vital capacity (FVC) ≤ 45% of predicted for gender, age, and height.

          2. Any prior use of non-invasive ventilation (NIV) outside of sleep (nighttime or naps).

          3. Any pulmonary or cardiac disorder or other medical disorder that would be a
             contraindication for general anesthesia or DPS hardware implantation in the chest.

          4. Implanted electrical device such as a pacemaker or cardiac defibrillator.

          5. Known diaphragm abnormality such as hiatal hernia or para-esophageal hernia of
             abdominal contents into the thoracic cavity.

          6. Participation in another treatment research study for people with ALS.

          7. Exposure to any other agent currently under investigation for the treatment of people
             with ALS (off-label use or investigational) within 30 days of the Screening Visit.

          8. Clinically significant history of unstable or severe cardiac, oncologic, hepatic,
             psychiatric, renal disease, or other medically significant illness.

          9. Pregnant women or women currently breastfeeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Shefner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York - Upstate Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Pacific Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Casey Brescia</last_name>
    <phone>617-643-7434</phone>
    <email>cbrescia@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gale Kittle</last_name>
      <phone>602-406-4792</phone>
      <email>gale.kittle@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Shafeeq Ladha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Allred</last_name>
      <phone>310-248-7645</phone>
      <email>allredp@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Richard Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanna Kushner</last_name>
      <phone>415-600-3758</phone>
      <email>KushneG@cpmcri.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle McFall</last_name>
      <phone>650-497-3079</phone>
      <email>dmcfall@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Yuen So, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela DeSaro</last_name>
      <phone>904-953-6915</phone>
      <email>desaro.pamela@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Boylan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrea Swenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Gonterman</last_name>
      <phone>617-726-0563</phone>
      <email>fgonterman@partners.org</email>
    </contact>
    <investigator>
      <last_name>James Berry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health Systems</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Foley</last_name>
      <phone>313-916-3955</phone>
      <email>helen@neuro.hfh.edu</email>
    </contact>
    <investigator>
      <last_name>Ximena Arcila-Londono, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Associates P.C.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gary Pattee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Kaplan</last_name>
      <phone>646-797-8657</phone>
      <email>kaplanL@hss.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Kassebaum</last_name>
      <phone>646-797-8592</phone>
      <email>kassebaumN@hss.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dale Lange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea McGlond</last_name>
      <phone>315-464-6409</phone>
      <email>mcglonda@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Anuradha Duleep, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mozhdeh Marandi</last_name>
      <phone>336-713-8577</phone>
      <email>mmarandi@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>James Caress, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Pineda</last_name>
      <phone>614-685-5661</phone>
      <email>colleen.pineda@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Agriesti</last_name>
      <phone>614-293-4098</phone>
      <email>julie.agriesti@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Quick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence ALS Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Hoke</last_name>
      <phone>503-962-1171</phone>
      <email>nancy.hoke@providence.org</email>
    </contact>
    <investigator>
      <last_name>Kimberly Goslin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Barr</last_name>
      <phone>267-507-2633</phone>
      <email>Christine.Barr@DrexelMed.edu</email>
    </contact>
    <investigator>
      <last_name>Terry Heiman-Patterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Rowlands</last_name>
      <phone>412-648-9053</phone>
      <email>doerdx@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>David Lacomis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Gorham</last_name>
      <phone>214-648-9518</phone>
      <email>nina.gorham@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Jaya Trivedi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Kittrell</last_name>
      <phone>210-450-0524</phone>
      <email>kittrellp@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Carlayne Jackson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://alsconsortium.org</url>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>August 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York - Upstate Medical University</investigator_affiliation>
    <investigator_full_name>Jeremy Shefner</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>DPS</keyword>
  <keyword>Diaphragm Pacing</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
